Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 - WOWK 13 Charleston, Huntington WV News, Weather, Sports

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024

http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharma_leader_series_top_25_ophthalmic_drug_manufacturers_2014_2024.html

Report Details

New study shows you commercial prospects for leading eye drug producers
What does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 235 page report provides 152 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. We analyse the 38 leading companies for eye medicines, to help you see the future of that industry and market. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Professor David T. Shima, PhD, Institute of Ophthalmology, University College London
- Sean Ainsworth, CEO and Founder, RetroSense Therapeutics
- Philip G. Ralston, Jr., CEO, MacuCLEAR
- Dr. Michael Stewart, Associate Professor, Mayo Clinic
- Authority from a company in the industry (views provided anonymously)

Discover forecasts and discussions to help you stay ahead in knowledge

You will find revenue forecasts to 2024 for nine companies, 31 top drugs and the industry, with growth rates and market shares. Our investigation lets you assess the most lucrative areas of that industry, especially pharma companies at the forefront of treating eye disorders and diseases. We predict sales growth with many opportunities.
You can stay ahead in knowledge of the ophthalmic treatments market, benefiting your research and analyses. The following sections further highlight what you will find in our report.
See prospects for leading US manufacturers

Our report provides you with profiles and analyses for top companies based in the US:

• Allergan
• Merck
• Pfizer
• Regeneron
There you examine products, progress, results, R&D pipelines and companies' revenue potentials to 2024. Also, you find sales forecasts for brands such as Restasis, Lumigan, Eylea, Combigan and Cosopt.
You can assess strengths, weaknesses, opportunities and threats (SWOT factors). Also, you will find linked organisations, including alliances and licensing. Discover what the future holds. You see approvals and strategy too, and mergers and acquisitions (M&A activity).

What are the outlooks for leading European producers?

Our report shows you developments and prospects for leading European pharma manufacturers developing and producing medicines for optical disorders:
• Novartis
• Roche
You find outlooks to 2024, including revenue forecasting, as well as R&D and commercial drivers and restraints. Also, you discover sales forecasting for brands such as Lucentis, Avastin, Azopt, Vigamox and Jetrea. We show where sales growth can occur.
What are the prospects for companies based in the Asia-Pacific region?
You see outlooks for top companies developing and producing ocular drugs based in the Asia-Pacific region. Assess product portfolios, other activities and revenue predictions to 2024:
• Santen
• Senju
• Valeant
You find sales prospects for brands such as Hyalein, Tapros/Taflotan, Cravit, and Diquas, along with R&D, strategies and driving and restraining forces from 2014 onwards.

Who are the leading emerging companies worldwide?

Our study also covers 29 other companies following after the world leaders. You discover activities of organisations including the following:
• Abbott
• Acucela
• Aerie Pharmaceuticals
• Aerpio Therapeutics
• Akorn
• Alimera Sciences
• Altheos
• Amakem
• Ampio Pharmaceuticals
• Bayer
• BioDiem
• Can-Fite BioPharma/OphthaliX
• Chengdu Kanghong Pharmaceutical
• Colby Pharmaceutical
• Eleven Biotherapeutics
• EyeGate Pharmaceuticals
• Gene Signal
• Icon Bioscience
• Lpath
• MacuCLEAR
• Neurotech
• Omeros
• Ophthotech
• Otsuka Pharmaceutical
• OXiGENE
• RXi Pharmaceuticals
• Shire
• Sirnaomics
• ThromboGenics
You see outlooks for a wide range of companies, from multinationals to emerging specialists in the eye disorders field. Find developments for treating visual disorders and sight loss.

You also find revenue predictions for the overall industry segment

Our report forecasts sales of ocular drugs by overall world market and product category. You see individual forecasted revenues and growth rates to 2024 for five world-level submarkets (therapeutic classes):
• Glaucoma
• Retinal disorders
• Ophthalmic allergy, inflammation and infection
• Dry eye
• Other agents
We predict total ophthalmic drug revenues to reach $20.9bn in 2014. We forecast high growth there to 2024. Discover the sales potential of the world market and find its most promising segments.

How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 report helps you

In summary, our 235 page report gives you the following knowledge:
• Profiles of 38 leading companies - discover product ranges, recent results, strategies and competition
• Outlooks for companies in eye medicine - assess top players worldwide, seeing opportunities, business data, challenges and commercial outlooks
• Forecasted ophthalmic drug revenues to 2024 for the top 9 companies - find predicted financial results for those medicines
• Predicted revenues of 31 leading drugs to 2024 - see potentials of top products
• Potential revenues to 2024 for the world ophthalmic drug market and 5 product categories (therapeutic classes) - find the industry's sales outlook
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

1. Executive Summary

1.1 Leading Ophthalmic Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.5 Drugs Considered for this Report
1.6 Glossary of Terms in this Report

2. Introduction to the Ophthalmic Drugs Market

2.1 The Eye: An Overview of Its Structure and Function
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the 'Silent Thief of Sight'
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome

3. Ophthalmic Drugs: World Market 2014-2024

3.1 The World Ophthalmic Drugs Market in 2012 and 2013
3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers 2014-2024
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2014-2024
3.5.1 Glaucoma Drugs Market: Sales Forecast 2014-2024
3.5.2 Retinal Disorders Drugs Market: Sales Forecast 2014-2024
3.5.3 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2014-2024
3.5.4 Dry Eye Drugs Market: Sales Forecast 2014-2024
3.6 Changing Market Shares by Segment 2014-2024
3.7 World Ophthalmic Drugs Market: Drivers and Restraints

4. Leading US Ophthalmic Drug Manufacturers in 2012 and 2013

4.1 Allergan
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Sales Forecast 2014-2024
4.1.1.2 Lumigan and Ganfort: Sales Forecast 2014-2024
4.1.1.3 Refresh Brand Products: Sales Forecast 2014-2024
4.1.1.4 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024
4.1.1.5 Acular: Sales Forecast 2014-2024
4.1.2 Allergan: Ophthalmic Product Pipeline
4.1.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
4.1.2.2 Novadur (Intravitreal Brimonidine Implant)
4.1.2.3 AGN 208397 (Beclomethasone Intravitreal Injection)
4.1.2.4 Anti-VEGF DARPins (VEGF Inhibitors)
4.1.3 Allergan: Ophthalmic Revenue Forecast 2014-2024
4.1.4 Allergan: SWOT Analysis
4.2 Merck
4.2.1 Merck: Ophthalmic Product Portfolio
4.2.1.1 Trusopt: Sales Forecast 2014-2024
4.2.1.2 Zioptan: Sales Forecast 2014-2024
4.2.1.3 AzaSite (azithromycin)
4.2.2 Merck: Ophthalmic Product Pipeline
4.2.3 Merck: Revenue Forecast 2014-2024
4.2.4 Merck: Drivers and Restraints
4.3 Pfizer
4.3.1 Pfizer: Ophthalmic Product Portfolio
4.3.1.1 Xalatan/Xalacom: Sales Forecast 2014-2024
4.3.1.2 Macugen (Valeant/Pfizer)
4.3.2 Pfizer: Ophthalmic Product Pipeline
4.3.3 Pfizer: Revenue Forecast 2014-2024
4.3.4 Pfizer: SWOT Analysis
4.4 Regeneron
4.4.1 Regeneron: Ophthalmic Product Portfolio
4.4.1.1 Eylea: US Sales Forecast 2014-2024
4.4.2 Regeneron: Ophthalmic Product Pipeline
4.4.3 Regeneron: Revenue Forecast 2014-2024
4.4.4 FDA Approves Zaltrap (aflibercept)
4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.4.6 Regeneron: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers in 2012 and 2013

5.1 Novartis (including Alcon)
5.1.1 Novartis: Ophthalmic Product Portfolio
5.1.1.1 Lucentis (ranibizumab)
5.1.1.2 Lucentis: Non-US Sales Forecast 2014-2024
5.1.1.3 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024
5.1.1.4 Vigamox: Sales Forecast 2014-2024
5.1.1.5 Azopt: Sales Forecast 2014-2024
5.1.1.6 Jetrea: Non-US Sales Forecast 2014-2024
5.1.2 Novartis: Ophthalmic Product Pipeline
5.1.2.1 Lucentis (ranibizumab) For Myopic Choroidal Neovascularisation
5.1.2.2 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.1.2.3 AKB 9778 (Aerpio Therapeutics)
5.1.2.4 AL 78898A (Complement Factor Inhibitor, Alcon)
5.1.3 Novartis: Revenue Forecast 2014-2024
5.1.4 Novartis: SWOT Analysis
5.2 Roche
5.2.1 Roche: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: US Sales Forecast 2014-2024
5.2.1.2 Avastin: Sales Forecast 2014-2024
5.2.2 Roche: Ophthalmic Product Pipeline
5.2.2.1 Lampalizumab (RG7417)
5.2.3 Roche: Revenue Forecast 2014-2024
5.2.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers in 2012 and 2013

6.1 Santen
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2014-2024
6.1.1.2 Hyalein: Sales Forecast 2014-2024
6.1.1.3 Cosopt: Japan Sales Forecast 2014-2024
6.1.1.4 Tapros/Taflotan: Sales Forecast 2014-2024
6.1.1.5 Diquas: Sales Forecast 2014-2024
6.1.1.6 Cravit and Tarivid: Sales Forecast 2014-2024
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2014-2024
6.1.4 Santen Acquires Novagali Pharma
6.1.5 Santen: SWOT Analysis
6.2 Senju
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2014-2024
6.2.4 Senju: SWOT Analysis
6.3 Valeant
6.3.1 Valeant's Acquisition of Bausch and Lomb: Aggressive Expansion?
6.3.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals
6.3.3 Valeant: Ophthalmic Product Portfolio
6.3.3.1 Macugen (Valeant/Pfizer): A Drug in Decline
6.3.4 Valeant: Ophthalmic Product Pipeline
6.3.4.1 Latanoprostene Bunod (BOL 303259-X)
6.4.3.2 Mapracorat (BOL 303242-X)
6.3.5 Valeant: Revenue Forecast 2014-2024
6.3.6 Valeant: SWOT Analysis

7. Emerging Ophthalmic Drug Manufacturers in 2012 and 2013

7.1 Pipeline and Other Companies, 2012-2013
7.2 Notable Terminated Drug Candidates
7.3 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy
7.4 Acucela
7.5 Aerie Pharmaceuticals
7.6 Aerpio Therapeutics: Developing AKB 9778
7.7 Akorn
7.7.1 Cosopt/Cosopt PF: Sales Forecast 2014-2024
7.7.2 AzaSite: Sales Forecast 2014-2024
7.8 Alimera Sciences
7.8.1 Iluvien: Will It Gain FDA Approval?
7.8.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.9 Altheos
7.10 Amakem
7.11 Ampio Pharmaceuticals
7.12 Bayer
7.12.1 Eylea: non-US Sales Forecast 2014-2024
7.13 BioDiem
7.13.1 BDM-E: A High-Value Divestment?
7.14 Can-Fite BioPharma/OphthaliX
7.15 Chengdu Kanghong Pharmaceutical: Still Developing Conbercept?
7.16 Colby Pharmaceutical
7.16.1 CPC 551: A Potential Treatment for Geographic Atrophy in Dry AMD
7.17 Eleven Biotherapeutics
7.18 EyeGate Pharmaceuticals
7.19 Gene Signal
7.19.1 Aganirsen: Preventing Corneal Graft Rejection
7.19.2 GSK
7.19.3 Darapladib for Diabetic Macular Oedema
7.20 Icon Bioscience
7.21 Lpath
7.21.1 iSONEP: Antibodies Against Bioactive Lipids
7.22 MacuCLEAR
7.22.1 MC 1101: a Potential Therapy for Dry AMD
7.23 Neurotech
7.23.1 Renexus (NT 501) for Dry AMD
7.24 Omeros
7.25 Ophthotech
7.25.1 Fovista: A Strong Competitor for the AMD Market
7.25.2 ARC1905: Complement C5 Inhibitor
7.25.3 Has Volociximab Been Terminated?
7.26 Otsuka Pharmaceutical
7.27 OXiGENE: Developing Zybrestat for Wet AMD
7.28 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.29 Shire
7.29.1 Jerini Ophthalmic's JSM6427 and JPE 1375 Terminated?
7.29.2 Lifitegrast (SHP606) for Dry Eye
7.29.3 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.30 Sirnaomics: Acurita (STP601) Still in Preclinical Development?
7.31 ThromboGenics
7.31.1 Jetrea (ocriplasmin)
7.31.1.1 Jetrea: US Sales Forecast 2014-2024
7.31.2 TB 403: Anti-Placental Growth Factor

8. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024

8.1 Porter's Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]

9. Research Interviews

9.1 Interview with Professor David T. Shima, PhD, Institute of Ophthalmology, University College London, UK
9.1.1 On the Role of VEGF in Retinal Disorders
9.1.2 On Candidate Molecule E10030
9.1.3 On Candidate Molecule JSM 6427
9.1.4 On New Sustained Release Formulations
9.1.5 On Delta-Notch Signalling
9.1.6 Potential Clinical Crossovers Between Ophthalmology and Oncology
9.1.7 Commercial and Clinical Possibilities in the Ophthalmology Market
9.1.8 On the Possibilities of Research into the Endothelial Fenestra
9.2 Expert Interview 2: Authority from a Company in the Industry (Views Provided Anonymously)
9.2.1 Key Unmet Needs
9.2.2 Challenges Facing the Ophthalmic Sector
9.2.3 On Current Ophthalmic Treatments and Their Effectiveness
9.2.4 On Opportunities in the Ophthalmic Sector
9.3 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor, Michigan, USA
9.3.1 The Optogenetic Approach to Vision Restoration
9.3.2 Choosing Disease Targets and Delivery Vectors
9.3.3 The Regulatory Picture
9.3.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas
9.3.5 The Next Ten Years for Gene Therapy
9.4 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA
9.4.1 MC 1101: Identifying and Treating Chiou Syndrome
9.4.2 Preventing Dry AMD Progression
9.4.3 Treating the Root Cause of Dry AMD
9.4.4 Phase 3: Endpoints and Prospects for MC 1101
9.5 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida, USA
9.5.1 The Impact of Eylea
9.5.2 The Comparative Dosing Schedules of Eylea and Lucentis
9.5.3 Patient Transitioning to Eylea: Salvage Switching
9.5.4 Avastin after the CATT Study
9.5.5 Prospects for Eylea in Other Indications and Combinations
9.5.6 Future Possibilities in Wet AMD Treatment

10. Conclusions

10.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
10.2 The World Ophthalmic Drugs Market in 2012 and 2013
10.2.1 Leading Ophthalmic Drugs Market Segments
10.2.2 Leading Ophthalmic Drugs
10.2.3 Leading Ophthalmic Drug Manufacturers
10.3 World Ophthalmic Drugs Market Forecast 2014-2024
10.4 The Future of the Ophthalmic Drugs Market?
10.4.1 Increasing Revenue Concentration among Specialist Companies
10.4.2 The Rise of Generics
10.4.3 Small Companies Can Have a Big Impact
10.4.4 What Will Succeed in the Ophthalmic Drugs Market?

List of Tables

Table 1.1 Currency Exchange Rates, 2012
Table 2.1 ICD 10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments for Glaucoma, 2013
Table 2.3 Drug Treatments for AMD, 2013
Table 2.4 Drug Treatments for Ocular Allergy, 2013
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2013
Table 2.6 Selected Drug Treatments for Eye Infections, 2013
Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2012-2013
Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), 2012-2013
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Net Revenue ($m), Ophthalmic Drugs Revenue ($m), Market Share (%), 2012-2013
Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2013
Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2012-2018
Table 3.7 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2018-2024
Table 3.8 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.9 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.10 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2012, 2018 and 2024
Table 4.1 Allergan: Overview, 2012-2013
Table 4.2 Allergan: Ophthalmic Drug Products, 2013
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2002-2012
Table 4.4 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.5 Allergan: Lumigan Revenue ($m), AGR (%), CAGR(%), 2000-2012
Table 4.6 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.7 Allergan: Refresh Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.8 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.9 Allergan: Acular Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.10 Allergan: Revenues ($m) and Revenue Shares (%) by Region, 2012
Table 4.11 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.12 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 4.13 Merck: Overview, 2012-2013
Table 4.14 Merck: Trusopt Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.15 Merck: Zioptan Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.16 Merck: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.17 Pfizer: Overview, 2012-2013
Table 4.18 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.19 Pfizer: Macugen Revenue ($m), AGR (%), CAGR(%), 2004-2012
Table 4.20 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.21 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 4.22 Regeneron: Overview, 2012-2013
Table 4.23 Regeneron: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.24 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.25 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 5.1 Novartis: Overview, 2012-2013
Table 5.2 Novartis: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.3 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.4 Novartis: Vigamox Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.5 Novartis: Azopt Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.6 Novartis: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.7 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.8 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 5.9 Roche: Overview, 2012-2013
Table 5.10 Roche: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.11 Roche: Avastin Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.12 Roche: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.13 Roche: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 6.1 Santen: Overview, 2012-2013
Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, 2012-2013
Table 6.3 Santen: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.4 Santen: Hyalein Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.5 Santen: Cosopt Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.7 Santen: Diquas Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.8 Santen: Cravit and Tarivid Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.9 Santen: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.10 Santen: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 6.11 Senju: Overview, 2012-2013
Table 6.12 Senju: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.13 Senju: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 6.14 Valeant: Overview, 2012-2013
Table 6.15 Valeant: Selected Products Revenue ($m), 2010-2012
Table 6.16 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.17 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 7.2 Akorn: AzaSite Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 7.3 Bayer: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 7.4 ThromboGenics: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024

List of Figures

Figure 2.1 Structure of the Human Eye
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2012
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
Figure 2.4 Classification of Glaucoma, 2013
Figure 3.1 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2012
Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2013
Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m), 2012-2024
Figure 3.4 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2013
Figure 3.5 Glaucoma Drugs Market Forecast: Revenues ($m), 2012-2024
Figure 3.6 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2012-2024
Figure 3.7 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), 2012-2024
Figure 3.8 Dry Eye Drugs Market Forecast: Revenues ($m), 2012-2024
Figure 3.9 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2018
Figure 3.10 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2024
Figure 3.11 World Ophthalmic Drugs Market: Drivers and Restraints, 2014-2024
Figure 4.1 Allergan: Restasis Revenue ($m), 2002-2012
Figure 4.2 Allergan: Restasis Revenue ($m), 2012-2024
Figure 4.3 Allergan: Lumigan Revenue ($m), 2000-2012
Figure 4.4 Allergan: Lumigan and Ganfort Revenue ($m), 2012-2024
Figure 4.5 Allergan: Refresh Revenue ($m), 2012-2024
Figure 4.6 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), 2012-2024
Figure 4.7 Allergan: Acular Revenue ($m), 2012-2024
Figure 4.8 Allergan: Revenue Shares (%) by Region, 2012
Figure 4.9 Allergan: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.10 Allergan: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 4.11 Merck: Trusopt Revenue ($m), 2012-2024
Figure 4.12 Merck: Zioptan Revenue ($m), 2012-2024
Figure 4.13 Merck: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.14 Merck: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 4.15 Merck: Drivers and Restraints, 2014-2024
Figure 4.16 Pfizer: Xalatan/Xalacom Revenue ($m), 2012-2024
Figure 4.17 Pfizer: Macugen Revenue ($m), 2004-2012
Figure 4.18 Pfizer: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.19 Pfizer: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 4.20 Regeneron: Eylea Revenue ($m), 2012-2024
Figure 4.21 Regeneron: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.22 Regeneron: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 5.1 Novartis: Lucentis Revenue ($m), 2012-2024
Figure 5.2 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), 2012-2024
Figure 5.3 Novartis: Vigamox Revenue ($m), 2012-2024
Figure 5.4 Novartis: Azopt Revenue ($m), 2012-2024
Figure 5.5 Novartis: Jetrea Revenue ($m), 2012-2024
Figure 5.6 Novartis: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 5.7 Novartis: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 5.8 Roche: Lucentis Revenue ($m), 2012-2024
Figure 5.9 Roche: Avastin Revenue ($m), 2012-2024
Figure 5.10 Roche: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 5.11 Roche: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, 2012
Figure 6.2 Santen: Eylea Revenue ($m), 2012-2024
Figure 6.3 Santen: Hyalein Revenue ($m), 2012-2024
Figure 6.4 Santen: Cosopt Revenue ($m), 2012-2024
Figure 6.5 Santen: Tapros/Taflotan Revenue ($m), 2012-2024
Figure 6.6 Santen: Diquas Revenue ($m), 2012-2024
Figure 6.7 Santen: Cravit and Tarivid Revenue ($m), 2012-2024
Figure 6.8 Santen: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 6.9 Santen: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 6.10 Senju: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 6.11 Senju: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 6.12 Valeant: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 6.13 Valeant: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), 2012-2024
Figure 7.2 Akorn: AzaSite Revenue ($m), 2012-2024
Figure 7.3 Alimera Sciences: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.4 Bayer: Eylea Revenue ($m), 2012-2024
Figure 7.5 Gene Signal: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.6 Neurotech: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.7 Ophthotech: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.8 Shire: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.9 ThromboGenics: Jetrea Revenue ($m), 2012-2024
Figure 8.1 Porter's Five Forces Analysis of the Ophthalmic Drugs Market, 2014-2024
Figure 10.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2013
Figure 10.2 World Ophthalmic Drugs Market: Revenues ($bn), 2012-2024
Figure 10.3 Leading Ophthalmic Drugs Manufactuters: Revenues ($m), 2012-2024

Companies Listed

Abbott Laboratories (Abbott)
Abbvie
Acucela
Advanced Vision Research (acquired by Akorn)
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (subsidiary of Novartis)
Alimera Sciences
Allergan
Allergro Ophthalmics
Altheos
Amakem
Ampio Pharma
Asahi Glass
AstraZeneca
Aton Pharma (acquired by Valeant)
Banyu Pharmaceutical (part of Merck)
Bausch and Lomb (subsidiary of Valeant)
Bayer
Bayer Yakuhin (Japanese subsidiary of Bayer)
BioDiem
Biogen Idec
BioInvent International
Biovail Corporation (part of Valeant)
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiron Corportation (part of Novartis)
Chugai Pharmaceutical (part of Roche)
CIBA VISION (part of Novartis)
Ciba-Geigy (part of Novartis)
Colby Pharmaceutical Company (Colby)
CoMentis
Daiichi Sankyo
Eleven Biotherapeutics
Eli Lilly and Company (Lilly)
EyeGate Pharmaceuticals
Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
Fougera Pharmaceuticals (acquired by Novartis)
Gene Signal
Genentech (subsidiary of Roche)
Genzyme (subsidiary of Sanofi)
Gilead Sciences
GSK
ICN Pharmaceuticals (original Valeant company)
Icon Bioscience
Inamed Corporation (subsidiary of Allergan)
InSite Vision
Inspire Pharmaceuticals (acquired by Merck)
ISTA Pharmaceuticals (part of Valeant)
Jerini AG
Jerini Ophthalmic (part of Jerini AG)
Johnson & Johnson
Kestrel Ophthalmics
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuCLEAR
MacuSIGHT, Inc.
MAP Pharmaceuticals (acquired by Allergan)
Meda
Medicis Corporation (acquired by Valeant)
Merck & Co. (Merck)
MerLion Pharmaceuticals
MSD K.K. (part of Merck)
Mylan Pharmaceuticals
Mystic Pharmaceuticals
Neurotech
NicOx
Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
NovaBay Pharmaceuticals
Novagali Pharma (acquired by Santen)
Novartis
Novo (subsidiary of Novo Nordisk)
Novo Nordisk
Oakwood Laboratories
OcuSciences
Omeros
Onyx Pharmaceuticals
OphthaliX (part-owned by Can-Fite BioPharma)
Ophthotech
OPKO Health
Ora
OSI Pharmaceuticals
Othera Pharmaceuticals (acquired by Colby)
Otsuka Pharmaceutical
Oxford BioMedica
OXiGENE
Parke-Davis (subsidiary of Pfizer)
PDL BioPharma
Pfizer
Pharmacia (acquired by Pfizer)
Potentia Pharmaceuticals
Premacure
Procter & Gamble
pSivida
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
RetroSense Therapeutics
ReVision Therapeutics
Roche
RXi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co. (Santen)
SARcode Bioscience
Schering-Plough (part of Merck)
Senju
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
Senju USA Inc. (subsidiary of Senju)
Shire
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
SkinMedica (subsidiary of Allergan)
Spark Therapeutics
Symphony ViDA
Takeda Pharmaceutical
Teva
The Patent Board
ThromboGenics
Upjohn (acquired by Pfizer through Pharmacia)
Valeant Pharmaceuticals
Ventana Medical Systems (acquired by Roche)
Warburg Pincus LLC
Warner-Lambert (acquired by Pfizer)
Watson Pharmaceuticals
Wyeth Pharmaceuticals (part of Pfizer)

Other Organisations Mentioned in this Report

A*STAR Institute for Infocomm Research (Singapore)
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Council of Europe
Emory University
European Medicines Agency (EMA)
Foundation Fighting Blindness (FFB) (US)
Health Canada
Institute of Experimental Medicine (Russia)
Institute of Ocular Pharmacology, Texas A&M (US)
Institute of Ophthalmology, University College London (UK)
Intellectual Property Appellate Board (India)
International Diabetes Federation
Internet Archive
Japan Patent Office (JPO)
Mayo Clinic
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Monash University
National Eye Institute (NEI) (US)
National Health Service (NHS) (UK)
National Institute for Health and Care Excellence (NICE) (UK)
NHS Scotland
Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
Novartis Venture Funds (NVF) (part of Novartis)
Ophthalmology External Research Unit (part of Pfizer)
Ophthrisi (GSK research unit)
Rinat (Pfizer research unit)
Texas Emerging Technology Fund
Therapeutic Goods Administration (TGA) (Australia)
Tokyo University of Science
United States Food and Drug Administration (FDA)
University of Florida
University of Kentucky
University of Melbourne
University of Michigan
US Preventive Services Task Force (USPSTF)
US Securities and Exchange Commission (SEC)
World Health Organization (WHO)

Read the full report:
Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024

http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharma_leader_series_top_25_ophthalmic_drug_manufacturers_2014_2024.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.